Tian Y A, Johnson G, Ashcroft S J
Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital, Headington, Oxford, UK.
Diabetes. 1998 Nov;47(11):1722-6. doi: 10.2337/diabetes.47.11.1722.
Hypoglycemic sulfonylureas stimulate insulin release by binding to a regulatory subunit of plasma membrane ATP-sensitive K+ (K(ATP)) channels. The consequent closure of K(ATP) channels leads to depolarization, opening of voltage-dependent Ca2+ channels, Ca2+ influx, and a rise in intracellular [Ca2+]. Recently, however, it has been suggested that sulfonylureas may have an additional action on secretion, independent of changes in intracellular [Ca2+] but dependent on the activity of protein kinase C (PKC). We have investigated the mechanisms involved in the PKC-dependent effect of sulfonylureas on the secretion machinery in beta-cells. In MIN6 beta-cells permeabilized by streptolysin O, insulin release was stimulated by elevation of [Ca2+] from 10(-8) to 10(-5) mol/l. At a [Ca2+] of 10(-8) mol/l, insulin release from permeabilized beta-cells was stimulated by addition of GTP-gamma-S, or by addition of a phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA). TPA, but not GTP-gamma-S, also increased insulin release when [Ca2+] was 10(-5) mol/l. Insulin release from permeabilized beta-cells was stimulated by tolbutamide (0.1-1 mmol/l) at 10(-8) but not at 10(-5) mol/l Ca2+. The effect of tolbutamide was blocked either by inhibition of PKC or when phorbol ester-sensitive PKC isoforms were maximally stimulated by TPA. Meglitinide and glibenclamide also stimulated insulin release from permeabilized beta-cells. To assess the possibility that direct activation of PKC mediates the exocytotic response to sulfonylureas, we studied the effect of tolbutamide and glibenclamide on PKC activity. Purified brain PKC was not activated by tolbutamide or glibenclamide, whether tested in the absence or presence of phosphatidylserine or TPA, or at low or high [Ca2+]; nor was the total PKC activity in extracts of MIN6 beta-cells affected by tolbutamide. Neither tolbutamide nor glibenclamide elicited translocation of any isoform of PKC in intact or permeabilized beta-cells under conditions in which TPA evoked a marked redistribution of PKC alpha- and epsilon-isoforms. We conclude that although the plasma membrane K(ATP) channel-independent stimulation of exocytosis by sulfonylureas may require functional PKC, the mechanism does not involve a direct activation of the enzyme.
降糖磺脲类药物通过与质膜ATP敏感性钾离子(K(ATP))通道的调节亚基结合来刺激胰岛素释放。K(ATP)通道随之关闭导致去极化,电压依赖性钙离子通道开放,钙离子内流,细胞内[Ca2+]升高。然而,最近有人提出磺脲类药物可能对分泌有额外作用,不依赖于细胞内[Ca2+]的变化,但依赖于蛋白激酶C(PKC)的活性。我们研究了磺脲类药物对β细胞分泌机制的PKC依赖性作用所涉及的机制。在经链球菌溶血素O通透处理的MIN6β细胞中,[Ca2+]从10(-8)升高到10(-5)mol/L可刺激胰岛素释放。在[Ca2+]为10(-8)mol/L时,向通透处理的β细胞中添加GTP-γ-S或佛波酯12-O-十四酰佛波醇13-乙酸酯(TPA)可刺激胰岛素释放。当[Ca2+]为10(-5)mol/L时,TPA而非GTP-γ-S也增加了胰岛素释放。在10(-8)但非10(-5)mol/L Ca2+条件下,甲苯磺丁脲(0.1 - 1 mmol/L)可刺激通透处理的β细胞释放胰岛素。甲苯磺丁脲的作用可通过抑制PKC或当TPA最大程度刺激佛波酯敏感的PKC同工型时被阻断。瑞格列奈和格列本脲也刺激通透处理的β细胞释放胰岛素。为评估PKC的直接激活介导对磺脲类药物的胞吐反应的可能性,我们研究了甲苯磺丁脲和格列本脲对PKC活性的影响。纯化的脑PKC未被甲苯磺丁脲或格列本脲激活,无论在有无磷脂酰丝氨酸或TPA的情况下进行测试,还是在低或高[Ca2+]条件下;MIN6β细胞提取物中的总PKC活性也不受甲苯磺丁脲影响。在TPA引起PKCα和ε同工型明显重新分布的条件下,甲苯磺丁脲和格列本脲在完整或通透处理的β细胞中均未引起任何PKC同工型的转位。我们得出结论,尽管磺脲类药物对胞吐作用的质膜K(ATP)通道非依赖性刺激可能需要功能性PKC,但该机制并不涉及该酶的直接激活。